IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says

Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.

compass navigation — The drug industry is trying to figure out how to navigate the IRA • Source: Shutterstock

Merck & Co., Inc. CEO Rob Davis said the Inflation Reduction Act’s (IRA) drug-pricing policies are already affecting the company's R&D and business development decisions. Davis talked about grappling with the new US drug pricing policies, which will pave the way for Medicare drug price negotiations, while speaking at the Goldman Sachs Healthcare CEOs Unscripted Conference on 5 January.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Novartis Gains Further Renal Territory With Regulus Acquisition

30 Apr 2025

• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

30 Apr 2025

• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.